Digest Network Come funziona
Network
/
Società
Ir
Non verificato

Ironwood Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

34 comunicati stampa

Guarda tutti i comunicati
06/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
14/07/2026
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/05/2026
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Eventi
Fiere
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Industria
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Web e Social Network
Telefonia e Varie
Industria
Mercato azionario
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/05/2026
Analisi di mercato
Scienza
Medicina - Varie
Fitness
Sanità
Biotecnologia
Farmaceutica
Salute
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
23/04/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/03/2026
Web e Social Network
Eventi
Fiere
Biotecnologia
Farmaceutica
Salute
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Fonte
Ironwood Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0